|
WHO
map (new window)
Hepatitis A is world-wide in distribution and is especially prevalent in
the developing countries of Africa and Asia. The infection is spread by contaminated food,
water and shellfish, from dishes and cutlery and person to person. There is no carrier
state of hepatitis A. Hepatitis A can often be prevented by ensuring safe food and water,
by passive immunization with Immune globulin and with Hepatitis A vaccine. Immune globulin
is now seldom given to travellers Hepatitis A vaccine is given instead. The vaccine is
given in 2 doses, one prior to travel, the second in 6-12 months (cost $60 per dose).
Protection lasts at least a year after the 1st. dose and after the 2nd. dose for 20 to 30
years or more. Side effects from this vaccine are usually mild (mainly being a sore arm).
The older single strength vaccine was given in 3 doses. (cost $40 per dose) Persons who
were born and raised in areas with high risk of hepatitis A returning to visit are likely
immune and therefore at low risk. Children can catch hepatitis A but usually have mild
symptoms and then are immune for the rest of their lives. They can transmit the disease to
others after they return if their symptoms are mild. Childrens dose of the vaccine
is $30.
Hepatitis B is a worldwide disease with carrier rates from .1% to 15% in various
populations. The transmission of hepatitis B can be by inoculation with a contaminated
needle, blood transfusion, sexual contact, intimate physical contact of any type and
indirect routes such as shared razors. Vaccination is recommended for at risk persons 3
months of age and older. The risk depends on destination and on occupation. Health care
workers should be immunized if they are likely to come in contact with blood.
Missionaries, diplomats and military personnel traveling in North Africa, Sub Sahara
Africa and South East Asia should be immunized if they plan to reside for more than 6
months in areas with high levels of endemic hep B and who will have close contact with the
local population. Immunization of adults consists of 3 or 4 injections given
intramuscularly on day 0, at 1 month and 6 months (or 0, 1, 2 and 12 months or 0, 7-10
days, 21 days and 1 year). The vaccine costs $30 per dose. At the present time booster
doses are thought to be unnecessary.
Hepatits A & B
For adults who need both Hepatitis A and Hepatitis B protection, a new combined
Hep.A and Hep.B vaccine is now available. The primary course of vaccination consists of
three (3) doses, costing $60 each, it should be administered at 0, 1 month and 6 months.
Children's vaccine is given at the same time interval and costs $30 per dose.
This is a mosquito borne viral encephalitis which may occur in epidemics in late summer
and autumn in the temperate areas of Bangladesh, Burma, Kampuchea, China, India, Japan,
Korea, Laos, Nepal, Thailand and eastern areas of the USSR. In endemic areas (tropical
areas of Philippines, Singapore, Sri Lanka, Taiwan, Malaysia, Indonesia, southern India
and southern Thailand) where there is no seasonal pattern, the risk is lower but
occasional outbreaks occur.
The mosquitoes are present in greatest numbers from June through September and feed
outdoors beginning at dusk and during evening hours. Thus, general protection measures
used against malaria are also important in avoiding J.E.
The vaccine is recommended for persons planning longterm residence in countries
experiencing epidemic Japanese Encephalitis, especially when travel is in rural areas
(particularly rice culture and pig farming) and during the months of risk. Short term
travelers (less than 1 month) especially those to urban centres are at low
or negligible risk. The new vaccine has less side effects and is given in 2
doses one month apart
CATMAT
recommendations
CDC
info and risk table
CDC
MAP meningitis belt
This vaccine is of benefit to travelers to countries recognized as having an epidemic of
meningococcal meningitis. There is an area of sub-Saharan Africa which has a high risk of
meningococcal disease known as the meningitis belt including Chad, Ethiopia, Sudan, Niger,
Nigeria, Ghana, Togo, and Upper Volta. Consideration should be given to vaccinating those
going to live or work in these areas for more than 3-4 weeks. Only mild local reactions
occur. It is effective for 3-5 years
Reports of meningococcal outbreaks
CATMAT
recommendations
In developing countries measles causes significant mortality. Most persons born before
1957 are likely to have been infected naturally and can be considered immune. It is
advisable that travelers be immune to measles. In Canada measles vaccine is administered
as Mumps Measles Rubella (MMR) to children at 12 months of age. Children 6-12 months old
may be immunized with measles vaccine if they will be in contact with young children in
the country being visited. Children vaccinated before 12 months of age should be
revaccinated at about 15 months of age. Rubella vaccination should be given to all women
of child bearing age who are not immune and Mumps vaccination is recommended for adults
with no history of mumps or prior immunization. The vaccines are available individually
but the MMR combination is frequently used. These are live vaccines and should not be used
in pregnancy or in persons who are immune suppressed.
Rabies is a viral disease which is worldwide. Only those who are likely to come in
intimate contact with wildlife (veterinarians, wildlife conservation personnel, biologists
etc.) are at high risk and should be immunized. It is administered in three intramuscular
doses on day 0, 7, and 21 or 28. The cost of one dose is about $125.00. An alternative
dosage is .1cc. intradermal. If a previously immunized person is exposed to rabies, two
post exposure doses should be given, one immediately and one three days later.
CATMAT
recommendations
CIWEC
Clinic Risk of Rabies in Nepal
CIWEC homepage
In Ontario the vaccines for tetanus, diphtheria and polio are now being used for primary
immunization. Travelers to both high and low risk areas should have these immunizations up
to date. Tetanus should be updated every 10 years. It is advisable to give a booster if it
is over 5 years and it is unsafe (because of the risk of aids or Hepatitis B or C from
reused needles) to get a booster (if injured) in the country visited. Polio vaccine and
diphtheria toxoid are effective for ten years.
Children's primary series of vaccines also include
pertussis (whooping cough) there is a new tetanus diphtheria vaccine
for adults which includes an adult booster of pertussis (ADACEL) This
vaccine is not yet covered by provincial health plans, cost- $40.
Medical personnel, missionaries, teachers and some children staying in endemic areas for
prolonged periods of time in particular are at risk. A traveler at high risk should have a
TB skin test done prior to departure (if they have not been previously immunized with a
vaccine occasionally used called BCG). When this is negative the traveler should be
advised to have a repeat tuberculin test every 1-2 years. If the skin test turns positive
treatment may be considered depending on age and circumstances. BCG is not indicated if
periodic skin testing is practical.
CATMAT
-TUBERCULOSIS SCREENING AND THE INTERNATIONAL TRAVELLER

Typhoid occurrences are worldwide and unique to man. There are no known animal carriers of
typhoid. It is prevalent in Africa, Asia, Central and South America, and in Eastern
Europe. Typhoid vaccine is recommended when the traveler is exposed to unsafe food or
water supply (the high risk traveler). Typhoid immunization provides protection against
moderate amounts of ingested bacteria. There are now 2 new typhoid vaccines. A live oral
vaccine, Vivotif, (a series of 4 capsules taken over a week or 3 doses of a liquid over 5
days) which cannot be taken with antibiotics, should be taken on an empty stomach and must
be kept refrigerated (cost ~$30). A new injectable vaccine, Typhim Vi, which is given in a
single dose and is good for 3 years. (cost ~$30). It has very few side effects and if
necessary can be given as young as 2 years of age. The injectable vaccine is effective
more quickly than the oral
Tick
Borne Encephalitis (TBE)
A vaccine is manufactured in Austria and should be
considered for long-term travellers to rural areas of parts of Europe, but
the time factor would preclude its use for short-term tourists (who are at
lower risk). The recommended regime is 3 doses of vaccine, the second dose
usually being given 1 - 3 months after the first (but this can be shortened
to 2 weeks) and the third after 9 - 12 months. This vaccine is now available in
Canada. Please let us know when you book your appointment so we can order
enough vaccine
Health
Canada information on TBE
map
of disease distribution in Europe from Vaccine manufacturer
(click on area of map to zoom)
Lyme
disease
This
vaccine is unavailable from the manufacturer at the present time
Lyme disease vaccine is a series of shots at 0, 1 month and 12 months.
Protection is 60% or more after 2 doses and over 80% after all three.
The area of highest risk for Lyme disease is the Northeastern United States and parts
of Canada which border on this area.
Lyme disease vaccine is recommended for adults and adolescents 15 years of age or older
who need protection against Lyme disease and asymptomatic infection caused by the strains
of B. burgdorferi endemic to the North American continent. (B. burgdorferi is the
cause of lyme disease.)
Individuals who are at risk of infection with B. burgdorferi include
| People working outdoors;- Camp counselors
- Camp-site concessionaires
- Certain construction personnel (i.e., those clearing building sites or grass or
brush)
- Farmers
- Foresters
- Forest rangers/park rangers
- Game wardens
- Landscapers
- Military personnel
- Police
- Workers on cattle, horse or dude ranches |
People using grassy or wooded outdoor areas recreationally; -
Campers
- Fishermen
- Gardeners
- Golfers
- Hikers
- Hunters
- Those playing in grassy areas
People traveling to endemic areas
Others;
- Pet owners
People with a prior history of Lyme disease or infection. |
Previous infection with B.
burgdorferi (Lyme disease) may not confer protective immunity against subsequent infection
and, therefore, may serve as a marker for those at risk for reinfection. Individuals with
Lyme disease that is no longer active may benefit from the vaccine.
Chickenpox
(Varicella)
Chickenpox is a highly contagious disease. In the United States
about 4 million people are infected each year, most are children 5 to 9 years
of age. Chickenpox is generally a mild disease in healthy children, but it can lead
to serious complications such as bacterial infections and pneumonia. In the United States
there are about 100 deaths and 10,000 people hospitalized. Chickenpox vaccine (Varivax)
is recommended by the American Academy of Pediatrics and the Advisory Committee on
Immunization Practices to the Centers for Disease Control and Prevention for universal use
in early childhood and for immunization in susceptible older children and adolescents.
Canadian recommendations are not yet published. A single 0.5 mL injection of
Varivax is recommended for children age 12 months to 12 years; two 0.5 mL
injections four to eight weeks apart are recommended for adolescents and adults
Main Service charges Links Diseases
Subject to IHR Other Vaccines Malaria When You Return
,
, |